AZTR News

Azitra, Inc. Announces Pricing of $1.5 Million Private Placement Priced At a Premium To Market Under NYSE Rules

Azitra, Inc. Announces Q3 2025 Results and Provides Business Updates

Azitra, Inc. Addresses False Report Regarding Sale of Securities

Azitra Receives Notice of Non-Compliance from NYSE American

Azitra, Inc. Expands Eligibility for ATR-04 Phase 1/2 Clinical Trial to Include Patients with Rashes due to KRAS and MEK Inhibitors

Azitra, Inc. Announces Revitalizing Results from Ex Vivo Study of ATR-COSF Demonstrating Ability to Reduce Fine Lines and Improve Elasticity in Human Skin